Your email has been successfully added to our mailing list.

×
0.165467625899281 0.0791366906474819 0.143884892086331 0.107913669064748 0.0611510791366906 0.0507194244604317 0.0665467625899281 0.0667266187050359
Stock impact report

SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback

SELLAS Life Sciences Group, Inc (SLS)  More Company Research Source: GlobeNewswire
Last sellas life sciences group, inc earnings: 11/14 04:41 pm Check Earnings Report
PDF NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced feedback from a Type C review with the U.S. Food and Drug Administration (FDA) regarding its clinical development program for nelipepimut-S (NPS) in patients with triple negative breast cancer (TNBC).  Based on written feedback from the FDA and on the totality of clinical, safety and translational NPS data presented to date, the Company has finalized the design and plan for a Phase 3 registration-enabling study of NPS in combination with trastuzumab for the treatment of patients with TNBC in the adjuvant setting after standard treatment.  If successful, this study may be considered as the basis for a Biologics License Application (BLA) submission to the FDA.    “We are indeed pleased with the feedba [Read more]
Impact snapshot Event time: SLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
SLS alerts
from News Quantified
Opt-in for
SLS alerts

from News Quantified
Opt-in for
SLS alerts

from News Quantified